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ABSTRACT
Background: A dry powder inhaler of KP-496 is currently in clinical development in Japan as an anti-
asthmatic agent. The aim of this study was to evaluate the in vitro pharmacological profile of KP-496.
Methods: The antagonistic activities of KP-496 for leukotriene (LT) D4 and thromboxane (TX) A2 receptors
were examined using the LTD4 - and U46619-induced contractions of the isolated guinea pig trachea. The se-
lectivity of KP-496 was examined using various agonist-induced contractions in the isolated guinea pig trachea.
Results: KP-496 produced parallel rightward shifts of the LTD4 and U46619 concentration-response curves in
a concentration-dependent manner. Schild plot analyses of the antagonistic activities of KP-496 demonstrated
that it is a competitive antagonist for LTD4 and TXA2 receptors with pA2 values of 8.64 and 8.23, respectively.
The LTD4 antagonistic activity of KP-496 was comparable to that of pranlukast and zafirlukast but was more po-
tent than that of montelukast. The TXA2 antagonistic activity of KP-496 was comparable to that of seratrodast.
KP-496 and seratrodast also inhibited the prostaglandin (PG) D2 - and PGF2α-induced contractions of the iso-
lated guinea pig trachea. KP-496 had no effect on the histamine-, acetylcholine-, serotonin- and substance P-
induced contractions of the isolated guinea pig trachea.
Conclusions: These results indicate that KP-496 is a selective dual antagonist for LTD4 and TXA2 receptors.
LTD4 and TXA2 play important roles in asthma, and antagonists for these mediators are being used for the
treatment of asthma. Thus, KP-496 is expected to become a novel potent therapeutic agent for asthma.
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INTRODUCTION
Bronchial asthma is characterized by reversible air-
way obstruction, bronchial hyperresponsiveness and
chronic inflammation. It has been reported that vari-
ous chemical mediators and cytokines are involved in
the onset and development of asthma. Leukotriene
(LT) D4 and thromboxane (TX) A2 are chemical me-
diators and arachidonic acid metabolites.1,2 LTD4 and
TXA2 induce airway smooth muscle contraction 3-6
and increase the development of mucosal edema.7-10
Furthermore, LTD4 increases mucosal secretion,11,12
and TXA2 causes airway hyperresponsiveness . 13,14
Thus, these mediators are thought to play important
roles in the pathogenesis of asthma. Therefore, the
regulation of their activities would provide therapeu-
tic benefits for asthmatic patients . Currently , some
potent LTD4 receptor antagonists, such as montelu-
kast,15 pranlukast16 and zafirlukast,17 and the TXA2
receptor antagonist, seratrodast,18 are being used for
the treatment of asthma.
LTD4 and TXA2 exert their biological effects via dif-
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Fig. 1 Efect of KP-496 on the LTD4 concentration-re-
sponse curves of the guinea pig trachea. The results are ex-
pressed as the percentage of the response induced by 1.0 
× 10－6 M carbachol and are the mean ± SD of 6 to 34 
experiments. ●, control; ○, 3 × 10－10 M KP-496; ▲, 1 × 
10－9 M  KP-496; △, 3 × 10－9 M KP-496; ■, 1 × 10－8 M 
KP-496; □, 3 × 10－8 M KP-496.
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ferent pathways. This suggests that a dual antagonist
for both of these mediators may become a more po-
tent and beneficial agent for the treatment of asthma
than LTD4 receptor antagonists and the TXA2 recep-
tor antagonist that have been launched. Based on this
concept , KP-496, a novel dual antagonist for LTD4
and TXA2 receptors, was synthesized and is currently
in clinical development as a dry powder inhaler. In
the present study, we evaluate the in vitro pharma-
cological profile of KP-496.
METHODS
ANIMALS
Male Hartley guinea pigs (six weeks old, 350―400 g )
were purchased from JAPAN SLC (Hamamatsu, Ja-
pan). The handling and treatment of the animals were
in accordance with the guidelines of the Japanese As-
sociation for Laboratory Animal Science (1987).
DRUGS AND CHEMICALS
KP-496 and montelukast were synthesized by Kaken
Pharmaceutical Co., Ltd. (Tokyo, Japan). Pranlukast,
zafirlukast and seratrodast were purified from the
commercially available ONON® (Ono Pharmaceutical
Co., Ltd., Osaka, Japan), ACCOLATE® (AstraZeneca,
London, UK) and BRONICA® (Takeda Pharmaceuti-
cal Co . , Ltd . , Osaka , Japan) , respectively . LTD4,
U46619, prostaglandin (PG) D2 and PGF2α were pur-
chased from Cayman Chemical Co. (Ann Arbor, MI,
USA). Histamine (histamine dihydrochloride) , ke-
totifen (ketotifen fumarate salt), serotonin, substance
P, ketanserin, salbutamol and procaterol (procaterol
hydrochloride ) were purchased from Sigma ( St .
Louis, MO, USA). Carbachol (carbamylcholine chlo-
ride), indomethacin, acetylcholine (Ach) and atropine
( atropine sulfate ) were purchased from Nacalai
Tesque, Inc . (Kyoto , Japan) . Salmeterol was pur-
chased from Tocris (Bristol , UK ) . L-732,138 (N-
Acetyl-L-tryptophan 3, 5-bis ( trifluoromethyl )benzyl
ester) was purchased from BIOMOL Research Lab
(Plymouth Meeting, PA, USA).
KP-496, pranlukast , montelukast , zafirlukast and
seratrodast were dissolved in dimethyl sulfoxide
(DMSO) and diluted with Tyrode solution (136.9 mM
NaCl , 2.7 mM KCl , 0.5 mM NaH 2PO 4, 1.0 mM
MgCl2・6H2O, 1.6 mM CaCl2・2H2O, 5.6 mM glu-
cose, 11.9 mM NaHCO3). In all experiments, the final
concentration of DMSO was adjusted to 0.01%.
PREPARATION OF ISOLATED GUINEA PIG TRA-
CHEA
Guinea pigs were sacrificed by exsanguination, and
the tracheae were immediately removed. Each tra-
chea was cut into 2-mm segments in a direction paral-
lel to the cartilage. These segments were cut open on
the other side of the smooth muscle and then four
sections were tied together by using a surgical adhe-
sive. Tracheal preparations thus obtained were sus-
pended in Magnus tubes containing Tyrode solution.
For the studies on the LTD4-induced contractile re-
sponses, 5.0 × 10−6 M indomethacin was added to Ty-
rode solution to inhibit the cyclooxygenase activity.
The tubes were maintained at 37℃ and continuously
aerated with 95% O2 and 5% CO2. The preparations
were subjected to a 1-g load, and each preparation
was equilibrated for 60 minutes. The responses of the
preparations were recorded on a pen recorder (U-
638, PANTOS Co., Ltd., Kyoto, Japan) via an isomet-
ric transducer (UM-203, Kishimoto Medical Instru-
ments, Kyoto, Japan).
CONCENTRATION-RESPONSE CURVES OF
LTD4- AND U46619-INDUCED GUINEA PIG TRA-
CHEAL CONTRACTIONS
At the beginning of the experiment , each tracheal
preparation was primed using 1.0 × 10−6 M carbachol
to check the contractility as well as to determine the
maximum contraction of the tracheal segments. After
washing with Tyrode solution and recovering to the
baseline, a control cumulative concentration-response
curve for LTD4 or U46619 was obtained by increasing
the concentration of either LTD4 or U46619. After ob-
taining the control concentration-response curve ,
each preparation was equilibrated by washing with
Tyrode solution and allowed to recover to the base-
line. Various concentrations of the test compounds
were added to the tubes and incubated for 30 min-
utes. Subsequently, a second concentration-response
curve was obtained for the same agonist.
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Fig. 2 Efect of KP-496, pranlukast, zafirlukast and montelukast on the 
LTD4-induced guinea pig tracheal contractions. The results are expressed 
as the percentage of the response induced by 6.6 × 10－9 M LTD4 and 
are the mean ± SD of four to six experiments. ＊＊, p＜0.01 compared with 
control (Dunnet’s multiple range test).
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Table 1 Efect of KP-496 on LTD4-induced Contractions of Guinea Pig Trachea
Schild plot analysis
pKBn
Concentration
(M) slope (95% CI)pA2 (95% CI)
0.988.648.91 ± 0.504 3×10 －10
KP-496
(0.75―1.22)(8.59―8.69)8.50 ± 0.4061×10 －9
8.48 ± 0.7063×10 －9
8.63 ± 0.1971×10 －8
8.71 ± 0.1373×10 －8
The results are expressed as the mean ± SD or the mean with 95% CI.
pA2 and slope were calculated from a linear regression-least square method.
n: the number of experiments
The contractile responses were expressed as the
percentage of the maximum contraction induced by
1.0 × 10−6 M carbachol. The antagonistic activity was
expressed as pA2 and pKB. The pA2 values were de-
termined by Schild plot analysis,19 whereas the pKB
values were determined by Furchgott’s method . 20
Furthermore, an estimate of the slope was also ob-
tained, since a slope of 1 in the Schild plot analysis is
indicative of a competitive antagonist.
AGONIST-INDUCED CONTRACTION OF GUINEA
PIG TRACHEA
At the beginning of the experiment, each preparation
was primed using the agonists (1.0 × 10− 6 M car-
bachol, 1.0 × 10−4 M histamine, 1.0 × 10−4 M Ach,
1.0 ×10−4 M serotonin, 1.0 × 10−6 M substance P, 1.0 ×
10−5M PGD2, 1.0 × 10−5 M PGF2α ) to check the con-
tractility as well as to determine the maximum con-
traction of the tracheal segments. After washing with
Tyrode solution and recovering to the baseline, a con-
trol contractile response was induced by each agonist
(6.6 × 10−9 M LTD4, 6.0 × 10−9 M U46619, 1.6 × 10−6 M
histamine, 8.5 × 10−7 M Ach, 3.0 × 10−7 M serotonin,
1.0 × 10−7 M substance P, 3.0 × 10−7 M PGD2, 2.0 ×
10−7M PGF2α). It was confirmed that these concentra-
tions induced stable contractions and were suitable to
investigate the antagonistic activities of the test com-
pounds in the preliminary study. After obtaining the
contractile response , each preparation was equili-
brated by washing with Tyrode solution and allowed
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Fig. 3 Efect of KP-496 on the U46619 concentration-re-
sponse curves of the guinea pig trachea. The results are ex-
pressed as the percentage of the response induced by 1.0 
× 10－6 M carbachol and are the mean ± SD of 6 to 27 
experiments. ●, control; ○, 3 × 10－9 M KP-496; ▲, 1 × 
10－8 M  KP-496; △, 3 × 10－8 M KP-496; ■, 1 × 10－7 M 
KP-496.
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Fig. 4 Efect of KP-496 and seratrodast on the U46619-in-
duced guinea pig tracheal contractions. The results are ex-
pressed as the percentage of the response induced by 6.0 
× 10－9 M U46619 and are the mean ± SD of four to five 
experiments. ＊＊, p＜0.01 compared with control (Dunnet’s 
multiple range test).
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Table 2 Efect of KP-496 on U46619-induced Contractions of Guinea Pig Trachea
Schild plot analysis
pKBn
Concentration
(M) slope (95% CI)pA2 (95% CI)
1.168.238.15 ± 0.4043×10 －9
KP-496
(0.83―1.49)(8.12―8.43)8.37 ± 0.5871×10 －8
8.20 ± 0.2263×10 －8
8.49 ± 0.3061×10 －7
The results are expressed as the mean ± SD or the mean with 95% CI.
pA2 and slope were calculated from a linear regression-least square method.
n: the number of experiments
to recover to the baseline. Various concentrations of
the test compounds were added to the tubes and in-
cubated for 30 minutes. Subsequently, a contractile
response was induced by the same agonist. The con-
tractile responses induced by LTD4 and U46619 were
expressed as the percentage of the contraction in-
duced by 6.6 × 10−9 M LTD4 and 6.0 × 10−9 M U46619,
respectively . The contractile responses induced by
the other agonists were expressed as the percentage
of the maximum contraction induced by each agonist
(1.0 × 10−4 M histamine, 1.0 × 10−4 M Ach, 1.0 × 10−4
M serotonin, 1.0 × 10−6 M substance P, 1.0 × 10−5 M
PGD2, 1.0 × 10−5 M PGF2α).
β2-AGONIST-INDUCED RELAXATION OF
GUINEA PIG TRACHEA
At the beginning of the experiment, each preparation
was primed using 1.0 × 10−6 M carbachol to check the
contractility as well as to determine the maximum
contraction of the tracheal segments. After washing
with Tyrode solution and recovering to the baseline,
each preparation was primed again using 1.0 × 10−6 M
carbachol. Five minutes after the contraction, a con-
trol cumulative concentration-response curve for a β2-
agonist was obtained by increasing the concentration
of the β2-agonist. After obtaining the first
concentration-response curve, each preparation was
equilibrated by washing with Tyrode solution and al-
lowed to recover to the baseline. Various concentra-
tions of the test compounds were added to the tubes
and incubated for 5 minutes. Subsequently, a second
concentration-response curve for the same β2-agonist
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Table 3 Efect of KP-496 on Various Agonists-induced Contractions of Guinea Pig trachea
Contraction (%)  nConcentration (M)CompoundAgonist (M)
59.17 ± 22.176―Control
KP-496
Histamine
(1.6×10 －6 )
74.07 ± 5.85 51×10 －7
69.32 ± 20.4651×10 －6
67.36 ± 17.4851×10 －5
＊＊23.49 ± 15.5261×10 －7Ketotifen
81.67 ± 10.775―Control
KP-496
Ach
(8.5×10 －7 )
84.37 ± 6.25 61×10 －7
77.64 ± 6.82 61×10 －6
90.80 ± 11.9151×10 －5
14.28 ± 9.93＊＊ 41×10 －7Atropine
113.18 ± 27.036―Control
KP-496
Serotonin
(3.0×10 －7 )
137.25 ± 22.1461×10 －7
128.61 ± 29.7361×10 －6
139.26 ± 24.1361×10 －5
7.68 ± 8.74＊＊61×10 －6Ketanserin
74.51 ± 5.39 4―Control
KP-496
Substance P
(1.0×10 －7 )
70.08 ± 8.60 41×10 －7
65.46 ± 9.71 41×10 －6
75.97 ± 7.08 41×10 －5
＊＊42.12 ± 10.0341×10 －5L-732, 138
84.05 ± 13.734―Control
KP-496
PGD2
(3.0×10 －7 )
75.05 ± 14.7141×10 －8
＊＊41.48 ± 23.4741×10 －7
26.54 ± 6.87＊＊41×10 －6
1.63 ± 3.26＊＊41×10 －5
24.09 ± 7.60＊＊41×10 －7Seratrodast
58.46 ± 11.824―Control
KP-496
PGF2α
(2.0×10 －7 )
56.40 ± 7.17 41×10 －8
51.57 ± 9.09 41×10 －7
＊＊28.69 ± 12.8141×10 －6
11.25 ± 9.76＊＊41×10 －5
＊＊28.16 ± 15.9741×10 －6Seratrodast
The results are expressed as the percentage of the maximum response induced by each agonist and are the mean ± SD. ＊＊, p＜
0.01 compared with control (Dunnet’ smultiple range test)
was obtained . The relaxation responses were ex-
pressed as the percentage of the maximum response
induced by 1.0 × 10 − 6 M carbachol . Only one
concentration-response curve was generated by sal-
meterol for each preparation because salmeterol
caused an irreversible relaxation, and the curves ob-
tained after the first and second cumulative addition
of salmeterol were not the same.
DATA ANALYSIS
All data are represented as the mean ± SD or the
mean with 95% CI. Statistically significant differences
were determined by Dunnett’s multiple range tests. A
p value of less than 0.05 was defined as significant.
RESULTS
LTD4-INDUCED CONTRACTION OF GUINEA PIG
TRACHEA
LTD4 induced concentration-dependent contractions
of the isolated guinea pig trachea. KP-496 produced
parallel rightward shifts of the LTD4 concentration-
response curves in a concentration-dependent man-
ner (Fig. 1). The pKB values were independent of the
KP-496 concentrations (Table 1 ) . The Schild plot
analysis indicated that the slope was not significantly
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Table 4 Efect of KP-496 on β2-agonist Concentration-response Curves of Guinea Pig Trachea
p valueEC50 (M)n
Concentration 
(M)
β2-agonist
 8.6×10 －816―Control
KP-496
Salbutamol
N.S.10.9×10 －8 41×10 －8
N.S.10.9×10 －8 41×10 －7
N.S.10.4×10 －8 41×10 －6
N.S. 9.6×10 －8 41×10 －5
 0.4×10 －812―Control
KP-496
Procaterol
N.S. 0.4×10 －8 31×10 －8
N.S. 0.5×10 －8 31×10 －7
N.S. 0.4×10 －8 31×10 －6
N.S. 0.4×10 －8 31×10 －5
14.0×10 －8 7―Control
KP-496
Salmterol
N.S. 8.9×10 －8 71×10 －8
N.S.21.6×10 －8 71×10 －7
N.S.12.3×10 －8 71×10 －6
N.S. 8.8×10 －8 71×10 －5
N.S. indicates no significant diference in EC50 values between control and KP-496-treated groups (Dunnet’ smultiple range test).
n: the number of experiments
different from unity, and the pA2 value of KP-496 was
8.64 (8.59―8.69, 95% CI)(Table 1).
KP-496, pranlukast and zafirlukast inhibited the
contractile response of the isolated guinea pig tra-
chea induced by LTD 4 ( 6.6 × 10 − 9 M ) in a
concentration-dependent manner and significantly in-
hibited the contractile response at 1 × 10−8 M. On the
other hand , montelukast significantly inhibited the
contractile response only at 1 × 10−7 M(Fig. 2).
U46619-INDUCED CONTRACTION OF GUINEA
PIG TRACHEA
U 46619 induced concentration-dependent contrac-
tions of the isolated guinea pig trachea. KP-496 pro-
duced parallel rightward shifts of the U 46619
concentration-response curves in a concentration-
dependent manner (Fig. 3). The pKB values were in-
dependent of the KP-496 concentrations ( Table 2 ).
The Schild plot analysis indicated that the slope was
not significantly different from unity , and the pA 2
value of KP-496 was 8.23 (8.12―8.43, 95% CI)(Table
2).
KP-496 and seratrodast inhibited the contractile re-
sponse of the isolated guinea pig trachea induced by
U46619 (6.0 × 10−9 M) in a concentration-dependent
manner, and significantly inhibited the contractile re-
sponse at 1 × 10−8 M (Fig. 4).
SELECTIVITY OF KP-496
The contractile responses induced by histamine, Ach,
serotonin and substance P were significantly inhib-
ited by the respective receptor antagonists (Table 3).
KP-496 (1 × 10−7 to 1 × 10−5 M) had no effect on
these responses. On the other hand, KP-496 signifi-
cantly inhibited the contractile responses of the iso-
lated guinea pig trachea induced by PGD2 and PGF2α
in a concentration-dependent manner (Table 3).
Salbutamol , procaterol and salmeterol increased
the relaxation responses of the isolated guinea pig
trachea in a concentration-dependent manner. KP-496
(1 × 10−8 to 1 × 10−5 M) had no effect on the relaxation
responses induced by salbutamol, procaterol and sal-
meterol ( Table 4 ).
DISCUSSION
In the present study, the pharmacological profile of
KP-496 was investigated using the isolated guinea pig
trachea. KP-496 produced parallel rightward shifts of
the LTD4 and U46619 concentration-response curves
in a concentration-dependent manner . Schild plot
analyses of the LTD4 and U46619 antagonistic activity
of KP-496 demonstrated that the slopes were not sig-
nificantly different from unity. Therefore, KP-496 is a
competitive dual antagonist for LTD4 and TXA2 recep-
tors.
At 1 × 10−8 M, KP-496, pranlukast and zafirlukast
significantly inhibited the LTD4-induced contraction.
However , montelukast significantly inhibited the
LTD4-induced contraction at a concentration of 1 ×
10−7 M. These results indicate that the antagonistic
activity of KP-496 is comparable to that of pranlukast
and zafirlukast and is more potent than that of mon-
telukast. This is in agreement with the previous re-
port which showed that the antagonistic activity of
pranlukast and zafirlukast is approximately ten times
more potent than that of montelukast.21 At 1 × 10−8 M,
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KP-496 and seratrodast significantly inhibited the
U46619-induced contraction. Therefore, the antago-
nistic activity of KP-496 is comparable to that of sera-
trodast. LTD4 receptor antagonists and the TXA2 re-
ceptor antagonist are used for the treatment of
asthma. These antagonists improve lung function and
reduce asthmatic symptoms and the use of bron-
chodilators. In the present study, the antagonistic ac-
tivities of KP-496 were not less potent than the activi-
ties of these antagonists; this indicates that KP-496
would also show such therapeutic effects through its
antagonistic activities for LTD4 and TXA2 receptors.
It has been reported that PGD2 and PGF2α are
bronchoconstrictors and that their activities are ex-
erted via their own receptors (DP and FP, respec-
tively) and the TXA2 receptor.22-24 KP-496 inhibited
the contractions induced by PGD2 and PGF2α in a
concentration-dependent manner. Seratrodast also in-
hibited these contractions. In the preliminary study,
the FP antagonist did not inhibit the contraction in-
duced by PGF2α (data not shown). These results sug-
gest that this in vitro functional assay evaluated the
antagonistic activity for contractions via the TXA2 re-
ceptor. Therefore, the antagonistic activity of KP-496
for the TXA2 receptor is thought to contribute to
these inhibitory effects on PGD2 - and PGF2α-induced
contractions.
Even at 1 × 10−5 M, KP-496 had no effect on the
histamine-, Ach-, serotonin- and substance P-induced
contractions, whereas at 1 × 10−8 M , KP-496 signifi-
cantly inhibited LTD4 - and U46619-induced contrac-
tions of the isolated guinea pig trachea. These results
indicate that the action of KP-496 is highly selective.
Further, at 1 × 10−5 M, KP-496 had no effect on the re-
laxations of the guinea pig trachea induced by β 2-
agonists such as salbutamol , procaterol and sal-
meterol. This result indicates that KP-496 does not
possess bronchodilator activity and has no effect on
the bronchodilator activity of β2-agonists. Therefore,
KP-496 might not prevent the therapeutic effects of
β2-agonists.
Recent studies demonstrated that chemical media-
tors such as LTD4 and TXA2 are involved in the
pathogenesis of asthma.25,26 LTD4 and TXA2 exert
their biological activities via different pathways ,
which suggests that inhibiting both these mediators
might have an even greater therapeutic efficacy. In
fact, it has been reported that the use of an LTD4 an-
tagonist in combination with a TXA2 antagonist or a
thromboxane synthesis inhibitor produced beneficial
therapeutic effects.27,28 Therefore, KP-496 might be-
come a more potent therapeutic agent for asthma
than the already launched single receptor antago-
nists.
Although LTD4 receptor antagonists and the TXA2
receptor antagonist are used, there are both respond-
ers and non-responders to these antagonists. The ra-
tio of urinary eicosanoids29,30 and genetic heterogene-
ity31,32 are related to the effects of these antagonists.
This suggests that the predominant mediator varies
from patient to patient. KP-496 is a dual antagonist for
LTD4 and TXA2 receptors; therefore, KP-496 is ex-
pected to be effective for a wide-range of asthmatic
patients, including those who are non-responders to
LTD4 receptor antagonists or the TXA2 receptor an-
tagonist.
In conclusion, this study showed that KP-496 is a
selective and potent dual antagonist for LTD4 and
TXA2 receptors, and KP-496 is expected to become a
useful therapeutic agent for asthma.
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